Currently, there are 106.45M common shares owned by the public and among those 98.97M shares have been available to trade.
The company’s stock has a 5-day price change of -28.89% and -50.55% over the past three months. RCKT shares are trading -53.78% year to date (YTD), with the 12-month market performance down to -78.43% lower. It has a 12-month low price of $6.26 and touched a high of $26.99 over the same period. RCKT has an average intraday trading volume of 1.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -29.47%, -38.57%, and -62.70% respectively.
Institutional ownership of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) shares accounts for 101.06% of the company’s 106.45M shares outstanding.
It has a market capitalization of $619.52M and a beta (3y monthly) value of 1.00. The earnings-per-share (ttm) stands at -$2.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.72% over the week and 6.74% over the month.
Earnings per share for the fiscal year are expected to increase by 10.43%, and 34.78% over the next financial year. EPS should grow at an annualized rate of 73.89% over the next five years, compared to -11.60% over the past 5-year period.
Looking at the support for the RCKT, a number of firms have released research notes about the stock. BMO Capital Markets stated their Outperform rating for the stock in a research note on March 12, 2025, with the firm’s price target at $50. Wedbush coverage for the Rocket Pharmaceuticals Inc (RCKT) stock in a research note released on December 30, 2024 offered a Outperform rating with a price target of $32. Goldman on their part issued Neutral rating on April 02, 2024.
